FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379649394> ?p ?o ?g. }

• W4379649394 abstract "<h3>Background</h3> Although several studies report a high incidence of pulmonary manifestations in SLE, lung involvement is often underestimated in SLE clinical assessment [1]. This is also mirrored by the absence of pulmonary manifestations other than pleurisy in the old and new classification criteria for SLE [2]. Moreover, limited evidence on the management of SLE-related pulmonary manifestations is available. <h3>Objectives</h3> To assess prevalence and clinical impact of the spectrum of SLE-related pulmonary manifestations and their association with patient autoantibody profiles in a large SLE cohort and to describe the effectiveness of different therapeutic approaches in distinct clinical settings. <h3>Methods</h3> Patients followed at the Lupus Clinics of ASST G. Pini-CTO and San Raffaele Hospital (Milan, Italy) were enrolled. Data regarding demographics, disease characteristics, autoantibody profile, pulmonary manifestations, damage accrual and treatment were collected. The following types of lung involvement were recorded: pleurisy, acute lupus pneumonitis, interstitial lung disease (ILD), alveolar haemorrhage, pulmonary embolism, arterial pulmonary hypertension and shrinking lung syndrome. <h3>Results</h3> Of the 471 SLE patients enrolled, we identified 78 patients (16.5%) displaying at least one pulmonary manifestation. Epidemiological data on each manifestation are reported in Table 1. Pleurisy was the most common pulmonary manifestations and manifested at disease onset in most cases (56%). Patient home environment (urban vs countryside) did not seem to impact the risk of developing lung disease. Damage accrual was relevant, as 2/3 of patients displayed at least 1 point increase in SLICC Damage Index (SDI) after the onset of lung involvement in comparison to baseline. All patients received at least one steroid course. Immunosuppressive treatment choices and efficacy differed among distinct manifestations: only half of the patients with pleurisy received immunosuppression, mainly azathioprine, with 100% of improvement, while 80% of cases of ILD received immunosuppression, predominantly mycophenolate, with a 50% risk of non-response. By comparing demographics and clinical characteristics among cases and controls, we found a significantly lower median age at disease onset (p=0.002) and a higher frequency of male sex (18% vs 9%; p=0.07), joint involvement (p=0.02) and constitutional symptoms (p=0.02) in patients with lung involvement, while no differences were observed in the autoantibody profile, including anti-dsDNA and anti-ENA autoantibodies. <h3>Conclusion</h3> Our study confirms that, in addition to the known epidemiological burden of pleurisy, other types of pulmonary involvement can complicate the disease course and contribute to damage accrual. In particular, ILD can frequently occur and respond to immunosuppressants in only half cases. Consistent with the association of lung involvement with increased morbidity, higher-risk categories for severe disease such as males and subjects with early-onset SLE were more represented among patients with pulmonary manifestations. <h3>References</h3> [1] Amarnani R, et al. Front. Med. 2021; 7:610257. [2] Aringer M, et al. Ann Rheum Dis. 2019; 78:1151-1159. [3] Smith EMD, Clin Immunol. 2019; 209:108274. [4] Ryu S, et al. Lupus Sci Med. 2017;):e000221. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Maria Gerosa: None declared, Giuseppe Alvise Ramirez: None declared, Lorenza Maria Argolini: None declared, Isabella Scotti: None declared, Carolina Artusi: None declared, Luca Moroni: None declared, Enrica Bozzolo: None declared, Maria Rosa Pellico: None declared, Ludovica Cavallo: None declared, Lorenzo Dagna: None declared, Roberto Caporali Speakers bureau: AbbVie, Amgen, BMS, Celltrion, Fresenius, Galapagos, Janssen, Lilly, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Fresenius, Galapagos, Lilly, Novartis, Pfizer, and UCB," @default.
• W4379649394 created "2023-06-08" @default.
• W4379649394 creator A5025464672 @default.
• W4379649394 creator A5031865451 @default.
• W4379649394 creator A5053288231 @default.
• W4379649394 creator A5056528659 @default.
• W4379649394 creator A5061329187 @default.
• W4379649394 creator A5066350505 @default.
• W4379649394 creator A5067547152 @default.
• W4379649394 creator A5069884400 @default.
• W4379649394 creator A5073254777 @default.
• W4379649394 creator A5075020183 @default.
• W4379649394 creator A5079037866 @default.
• W4379649394 date "2023-05-30" @default.
• W4379649394 modified "2023-10-06" @default.
• W4379649394 title "POS1518 PULMONARY INVOLVEMENT IN LUPUS IS ASSOCIATED WITH ENHANCED MORBIDITY: A MULTICENTRE STUDY" @default.
• W4379649394 doi "https://doi.org/10.1136/annrheumdis-2023-eular.525" @default.
• W4379649394 hasPublicationYear "2023" @default.
• W4379649394 type Work @default.
• W4379649394 citedByCount "0" @default.
• W4379649394 crossrefType "proceedings-article" @default.
• W4379649394 hasAuthorship W4379649394A5025464672 @default.
• W4379649394 hasAuthorship W4379649394A5031865451 @default.
• W4379649394 hasAuthorship W4379649394A5053288231 @default.
• W4379649394 hasAuthorship W4379649394A5056528659 @default.
• W4379649394 hasAuthorship W4379649394A5061329187 @default.
• W4379649394 hasAuthorship W4379649394A5066350505 @default.
• W4379649394 hasAuthorship W4379649394A5067547152 @default.
• W4379649394 hasAuthorship W4379649394A5069884400 @default.
• W4379649394 hasAuthorship W4379649394A5073254777 @default.
• W4379649394 hasAuthorship W4379649394A5075020183 @default.
• W4379649394 hasAuthorship W4379649394A5079037866 @default.
• W4379649394 hasBestOaLocation W43796493941 @default.
• W4379649394 hasConcept C126322002 @default.
• W4379649394 hasConcept C2776265017 @default.
• W4379649394 hasConcept C2776912625 @default.
• W4379649394 hasConcept C2777543607 @default.
• W4379649394 hasConcept C2777714996 @default.
• W4379649394 hasConcept C2778341716 @default.
• W4379649394 hasConcept C2778978224 @default.
• W4379649394 hasConcept C2779134260 @default.
• W4379649394 hasConcept C2779634585 @default.
• W4379649394 hasConcept C2780930700 @default.
• W4379649394 hasConcept C2781244666 @default.
• W4379649394 hasConcept C71924100 @default.
• W4379649394 hasConceptScore W4379649394C126322002 @default.
• W4379649394 hasConceptScore W4379649394C2776265017 @default.
• W4379649394 hasConceptScore W4379649394C2776912625 @default.
• W4379649394 hasConceptScore W4379649394C2777543607 @default.
• W4379649394 hasConceptScore W4379649394C2777714996 @default.
• W4379649394 hasConceptScore W4379649394C2778341716 @default.
• W4379649394 hasConceptScore W4379649394C2778978224 @default.
• W4379649394 hasConceptScore W4379649394C2779134260 @default.
• W4379649394 hasConceptScore W4379649394C2779634585 @default.
• W4379649394 hasConceptScore W4379649394C2780930700 @default.
• W4379649394 hasConceptScore W4379649394C2781244666 @default.
• W4379649394 hasConceptScore W4379649394C71924100 @default.
• W4379649394 hasLocation W43796493941 @default.
• W4379649394 hasOpenAccess W4379649394 @default.
• W4379649394 hasPrimaryLocation W43796493941 @default.
• W4379649394 hasRelatedWork W2430837994 @default.
• W4379649394 hasRelatedWork W2438891743 @default.
• W4379649394 hasRelatedWork W2517883208 @default.
• W4379649394 hasRelatedWork W2743918347 @default.
• W4379649394 hasRelatedWork W2883658117 @default.
• W4379649394 hasRelatedWork W3190722030 @default.
• W4379649394 hasRelatedWork W4309181476 @default.
• W4379649394 hasRelatedWork W4310329733 @default.
• W4379649394 hasRelatedWork W4327934586 @default.
• W4379649394 hasRelatedWork W4367606959 @default.
• W4379649394 isParatext "false" @default.
• W4379649394 isRetracted "false" @default.
• W4379649394 workType "article" @default.